Daniel  Skovronsky net worth and biography

Daniel Skovronsky Biography and Net Worth

Dan Skovronsky is the chief scientific and medical officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. He also has responsibility for global business development.

Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and senior vice president, clinical and product development.

Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his Ph.D. in neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.

What is Daniel Skovronsky's net worth?

The estimated net worth of Daniel Skovronsky is at least $139.28 million as of August 12th, 2025. Dr. Skovronsky owns 137,660 shares of Eli Lilly and Company stock worth more than $139,276,128 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Skovronsky may own. Additionally, Dr. Skovronsky receives an annual salary of $3,820,000.00 as SVP at Eli Lilly and Company. Learn More about Daniel Skovronsky's net worth.

How old is Daniel Skovronsky?

Dr. Skovronsky is currently 50 years old. There are 7 older executives and no younger executives at Eli Lilly and Company. The oldest executive at Eli Lilly and Company is Mr. Jeffrey N. Simmons, Senior VP & President of Elanco Animal Health, who is 57 years old. Learn More on Daniel Skovronsky's age.

What is Daniel Skovronsky's salary?

As the SVP of Eli Lilly and Company, Dr. Skovronsky earns $3,820,000.00 per year. The highest earning executive at Eli Lilly and Company is Mr. David A. Ricks, Chairman, CEO & President, who commands a salary of $6,290,000.00 per year. Learn More on Daniel Skovronsky's salary.

How do I contact Daniel Skovronsky?

The corporate mailing address for Dr. Skovronsky and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Daniel Skovronsky's contact information.

Has Daniel Skovronsky been buying or selling shares of Eli Lilly and Company?

Daniel Skovronsky has not been actively trading shares of Eli Lilly and Company during the last ninety days. Most recently, on Tuesday, August 12th, Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president now directly owns 137,660 shares of the company's stock, valued at $87,331,504. Learn More on Daniel Skovronsky's trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), J. Fyrwald (Director), Michael Harrington (VP), Jamere Jackson (Director), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Gabrielle Sulzberger (Director), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, Eli Lilly and Company insiders bought shares 5 times. They purchased a total of 4,514 shares worth more than $2,894,841.15. In the last year, insiders at the sold shares 1 times. They sold a total of 1,000 shares worth more than $818,240.00. The most recent insider tranaction occured on August, 12th when CEO David A Ricks bought 1,632 shares worth more than $1,052,264.64. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 8/12/2025.

Daniel Skovronsky Insider Trading History at Eli Lilly and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2025Buy1,000$634.40$634,400.00137,660View SEC Filing Icon  
6/14/2018Buy10,000$86.22$862,200.00View SEC Filing Icon  
See Full Table

Daniel Skovronsky Buying and Selling Activity at Eli Lilly and Company

This chart shows Daniel Skovronsky's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $1,011.74
Low: $1,007.18
High: $1,032.63

50 Day Range

MA: $913.15
Low: $724.73
High: $1,109.09

2 Week Range

Now: $1,011.74
Low: $623.78
High: $1,111.99

Volume

3,853,037 shs

Average Volume

3,914,035 shs

Market Capitalization

$956.48 billion

P/E Ratio

49.50

Dividend Yield

0.58%

Beta

0.37